Izicopan: A Best-in-Class Profile C5aR Inhibitor with Potential in ANCA Associated Vasculitis & Beyond
9:30 am - Wednesday 9th December 2026
- Exploring the potential of C5aR inhibition to advance outcomes for patients with ANCA-associated vasculitis and other complement-mediated diseases
- Highlighting the key characteristics of a next-generation complement therapeutic and the opportunities for differentiation within an evolving treatment landscape
- Examining the future role of targeted complement inhibition across renal, inflammatory, and immune-mediated indications
